Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs
Status:
COMPLETED
Trial end date:
2024-09-20
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if Rebamipide effective in gastroprotection in patients with atrial fibrillation who are treated with Direct Oral Anticoagulants (DOACs). Another point is to compare efficacy of Rebamipide and of its combination with Pantoprazole with efficacy of Pantoprazole only.
Participants will:
Take one of three variants of treatments for up to 24 weeks. Visits to the clinic wil take place for screening and then every 8 weeks.
Phase:
PHASE4
Details
Lead Sponsor:
Pirogov Russian National Research Medical University